Skip to main content
. Author manuscript; available in PMC: 2018 Apr 24.
Published in final edited form as: Clin Chem. 2017 Jul 5;63(10):1605–1613. doi: 10.1373/clinchem.2017.272849

Figure 4.

Figure 4

ND-NaME-PrO-HRM-MiSeq performed in circulating tumor DNA (ctDNA) containing mutations in 10 different targets obtained from metastatic breast cancer patients. (A, D) No-treatment samples without DSN were processed in parallel comparison. (B, E) Multiplexed mutation scanning pre-screening performed via multiplexed High Resolution Melting (HRM). (C, F). Variant frequency at the 10 mutated targets on cfDNA as derived via targeted re-sequencing (Miseq) for no-treatment samples (blue bars) and ND-NaME-treated samples (red bars).